Eagle Pharmaceuticals (NASDAQ:EGRX) Upgraded at ValuEngine

ValuEngine upgraded shares of Eagle Pharmaceuticals (NASDAQ:EGRX) from a hold rating to a buy rating in a research report released on Friday morning, ValuEngine reports.

EGRX has been the topic of several other reports. Cantor Fitzgerald reiterated a hold rating and set a $58.00 price objective on shares of Eagle Pharmaceuticals in a research report on Tuesday, May 7th. Mizuho reiterated a hold rating and set a $50.00 price objective on shares of Eagle Pharmaceuticals in a research report on Wednesday, April 24th. Royal Bank of Canada reiterated a buy rating and set a $66.00 price objective on shares of Eagle Pharmaceuticals in a research report on Sunday, August 11th. Zacks Investment Research upgraded Eagle Pharmaceuticals from a hold rating to a strong-buy rating and set a $66.00 price objective on the stock in a research report on Wednesday, August 14th. Finally, BidaskClub upgraded Eagle Pharmaceuticals from a hold rating to a buy rating in a research report on Saturday, August 10th. Three equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $58.80.

Shares of Eagle Pharmaceuticals stock opened at $58.93 on Friday. The company has a current ratio of 3.59, a quick ratio of 3.36 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $804.34 million, a PE ratio of 28.20 and a beta of 1.44. The business’s 50-day moving average price is $55.67 and its 200-day moving average price is $51.14. Eagle Pharmaceuticals has a 12 month low of $36.03 and a 12 month high of $82.33.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.31 by $0.17. The firm had revenue of $56.70 million for the quarter, compared to analyst estimates of $53.61 million. Eagle Pharmaceuticals had a return on equity of 24.10% and a net margin of 19.79%. The company’s revenue was down 4.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.99 EPS. As a group, analysts predict that Eagle Pharmaceuticals will post 2.48 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of EGRX. Norges Bank bought a new position in Eagle Pharmaceuticals during the 4th quarter worth approximately $10,948,000. LSV Asset Management grew its position in Eagle Pharmaceuticals by 200.2% during the 1st quarter. LSV Asset Management now owns 250,004 shares of the specialty pharmaceutical company’s stock worth $12,622,000 after acquiring an additional 166,715 shares during the last quarter. Invesco Ltd. grew its position in Eagle Pharmaceuticals by 50.4% during the 2nd quarter. Invesco Ltd. now owns 402,792 shares of the specialty pharmaceutical company’s stock worth $22,427,000 after acquiring an additional 134,931 shares during the last quarter. Man Group plc grew its position in Eagle Pharmaceuticals by 784.6% during the 2nd quarter. Man Group plc now owns 136,235 shares of the specialty pharmaceutical company’s stock worth $7,586,000 after acquiring an additional 120,835 shares during the last quarter. Finally, Federated Investors Inc. PA grew its position in shares of Eagle Pharmaceuticals by 326.8% in the 1st quarter. Federated Investors Inc. PA now owns 141,891 shares of the specialty pharmaceutical company’s stock worth $7,164,000 after buying an additional 108,649 shares during the last quarter. Institutional investors and hedge funds own 98.37% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.

Featured Story: What are no-load funds?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.